Advertisement

Chemotherapy and Novel Cancer Targeted Therapies

  • Milind D. RongheEmail author
  • Dermot Murphy
Chapter

Abstract

Overall survival from childhood malignancies has dramatically improved, with survival rates now reaching over 70 %. Although improvements in radiotherapy and surgery have reduced the late sequelae of curative therapy, chemotherapy still remains the mainstay of treatment for most childhood cancers. Nevertheless, some types of childhood cancer remain a difficult challenge, and for those who survive the burden of late effects can be considerable. The current paradigm for new cancer therapies is to increase our knowledge of the molecular basis of carcinogenesis, followed by the development of cancer-cell specific therapies. During the past 10 years, initiatives have been undertaken by paediatric oncologists to further promote the clinical evaluation of new anti cancer compounds in children within national academic paediatric groups. Through proper evaluation in collaborative clinical trials we will learn how best to use these new therapeutic approaches and improve the survival rates and reduce toxicity for children with cancer.

Keywords

Solid tumours Children Staging Treatment Chemotherapy Cytotoxic drugs Surgery Resistance Toxicity Targeted treatment 

References

  1. 1.
    Wallace WHB. Growth and endocrine function following the treatment of childhood malignant disease. In: Pinkerton CR, Plowman PN, et al., editors. Paediatric oncology: clinical practice and controversies. 2nd ed. London: Chapman and Hall Medical; 1997. p. 706–31. 29.Google Scholar
  2. 2.
    Bleyer WA. The impact of childhood cancer on the United States and the world. Cancer. 1990;40:355–67.Google Scholar
  3. 3.
    Lemerle J, Voûte PA, Tournade MF, et al. Effectiveness of preoperative chemotherapy in Wilms’ tumour: results of an international society of paediatric oncology (SIOP) clinical trial. J Clin Oncol. 1983;1(10):604–9.PubMedGoogle Scholar
  4. 4.
    Voûte PA, Tournade MF, Delemarre JFM, et al. Preoperative chemotherapy as first treatment in children with Wilms’ tumour. Results of SIOP nephroblastoma trials and studies. SIOP proceedings, Abstract 123, Jerusalem; 1987.Google Scholar
  5. 5.
    Tournade MF, Com-Nougue C, Voute PA, Lemerle J, De Kraker J, et al. Results of the Sixth International Society of Pediatric Oncology Wilms’ Tumour Trial and Study: a risk-adapted therapy approach in Wilms’ tumour. J Clin Oncol. 1993;11:1014–23.PubMedGoogle Scholar
  6. 6.
    Rickard KA, Loghman ES, Grosfeld JL, et al. Short and long-term effectiveness of enteral and parenteral nutrition in reversing or preventing protein energy malnutrition in advanced neuroblastoma; a prospective randomised study. Cancer. 1985;56:2881.CrossRefPubMedGoogle Scholar
  7. 7.
    Rickard KA, Coates TD, Grosfeld JL, et al. The value of nutritional support in children with cancer. Cancer. 1986;48:1904.CrossRefGoogle Scholar
  8. 8.
    Capra S, Ferguson M, Ried K. Cancer: impact of nutrition intervention outcome – nutrition issues for patients. Nutrition. 2001;9:769–72.CrossRefGoogle Scholar
  9. 9.
    UKCCSG. Annual scientific report. United Kingdom Children’s Cancer Study Group; 2009.Google Scholar
  10. 10.
    Wyllie AH. Apoptosis. Br J Cancer. 1993;67:205–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Takimoto C, Page R. Principles of chemotherapy. In: Pazdur R, Coia LR, Hoskins WJ, Wagman LD, editors. Cancer management: a multidisciplinary approach, vol. 3. 5th ed. New York: Oncology Group; 1991. p. 21–38.Google Scholar
  12. 12.
    Lum BL, Fisher GA, Brophy NA, Yahanda AM, Alder KM, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993;72(Suppl):3502–14.CrossRefPubMedGoogle Scholar
  13. 13.
    Pinkerton CR, Hardy JR. Cancer chemotherapy and mechanisms of resistance. In: Pinkerton CR, Plowman PN, et al., editors. Paediatric oncology: clinical practice and controversies, vol. 6. 2nd ed. London: Chapman and Hall Medical; 1997. p. 159–88.Google Scholar
  14. 14.
    Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727.PubMedGoogle Scholar
  15. 15.
    Wallace WHB, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. Br Med J. 2001;323:271–4.CrossRefGoogle Scholar
  16. 16.
    Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol. 2013;14(3):e95–103.Google Scholar
  17. 17.
    National Cancer Institute SEER Program. Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. Bethesda: National Cancer Institute; 1999.Google Scholar
  18. 18.
    Coley W. The treatment of malignant tumours by repeated inoculation of Erysipelas: With a report of 10 original cases. Am J Med Sci. 1893;105:487–511.CrossRefGoogle Scholar
  19. 19.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.CrossRefPubMedGoogle Scholar
  20. 20.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–69.CrossRefPubMedGoogle Scholar
  21. 21.
    Vassal G, Zwaan CM, Ashley D, Le Deley MC, Hargrave D, Blanc P, Adamson PC. New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncol. 2013;14:e117–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Arceci RJ, Cripe TP. Emerging cancer-targeted therapies. Pediatr Clin North Am. 2002;49:1339–68.CrossRefPubMedGoogle Scholar
  23. 23.
    Buchdunger E, Zimmermann J, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2- Phenylaminopyrimidine derivative. Cancer Res. 1996;56(1):100–4.PubMedGoogle Scholar
  24. 24.
    Stegmeier F, Warmuth M, Sellers WR, Dorsch M. Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther. 2010;87:543–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Adamson PC. Committee on shortening the time line for new cancer treatments. In: Adamson PC, Weiner SL, Simone JV, Gelband H, editors. Making better drugs for children with cancer. Washington DC: National Academies Press; 2005.Google Scholar
  26. 26.
    Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist. 2009;14:83–91.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381:125–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of pre-defined specificity. Nature. 1975;256:495–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Lynch DA, Yang XT. Therapeutic potential of ABX- EGA: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002;29:47–50.CrossRefPubMedGoogle Scholar
  31. 31.
    Waksal HW. Role of anti-epidermal growth factor receptor in treating cancer. Cancer Metastasis Rev. 1999;18(4):427–36.CrossRefPubMedGoogle Scholar
  32. 32.
    Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM, for the Children’s Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.Google Scholar
  33. 33.
    Simon T, Hero B, Faldum A, Handgretinger R, Schrappe M, Klingebiel T, Berthold F. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Worth LL, Jeha SS, Kleinermann ES. Biologic response modifiers in pediatric cancer. Hematol Oncol Clin North Am. 2001;15:723–40.CrossRefPubMedGoogle Scholar
  35. 35.
    Dillman R, Dselvan F, Schiltz D. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med. 2006;355:1179–81.CrossRefPubMedGoogle Scholar
  36. 36.
    Foster A, Rooney C. Improving T cell therapy for cancer. Expert Opin Biol Ther. 2006;6(3):215–29.CrossRefPubMedGoogle Scholar
  37. 37.
    Suntharalingan G, Perry MR, Ward S, et al. Cytokineand storm in a Phase I trial of the anti-CD28 monoclonal antibody PDN1412. N Engl J Med. 2006;335:1018–28.CrossRefGoogle Scholar
  38. 38.
    Krause D, Van Etten RA. Tyrosine Kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Paediatric OncologyRoyal Hospital for ChildrenGlasgowScotland, UK
  2. 2.Schiehallion UnitRoyal Hospital for Sick Children, YorkhillGlasgowScotland, UK

Personalised recommendations